(+) -Atuveciclib

CAT: 804-HY-12871ASize: 1 EachDry Ice: NoHazardous: No
1 EachSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
(+) -Atuveciclib is the isomer of Atuveciclib (Racemate) (HY-12871) . Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
CAS Number
[1414943-94-4]
Product Name Alternative
(+) -BAY-1143572
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/plus-atuveciclib.html
Smiles
COC1=C(C2=NC=NC(NC3=CC(CS(C)(=N)=O)=CC=C3)=N2)C=CC(F)=C1
Molecular Formula
C18H18FN5O2S
Molecular Weight
387.43
References & Citations
[1]Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML) . [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA) : AACR; Cancer Res 2016;76 (14 Suppl) :Abstract nr 3022.|[2]Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (15 Suppl) :Abstract nr DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName